每经AI快讯，有投资者在投资者互动平台提问：公司旗下爱森泽生物的虾青素，是天然藻源还是化学 合成？技术路线是什么？当前虾青素原料市场涨价明显，公司是否有提价计划、产能规划及成本控制措 施？ 沃森生物（300142.SZ）2月26日在投资者互动平台表示，目前为天然藻源。关于相关产品和项目的后续 情况请持续关注公司披露的信息。 （文章来源：每日经济新闻） ...

Core Viewpoint - The recent release of three group standards for astaxanthin production by Nanjing University of Technology marks a significant step in standardizing production technology in China, providing essential technical support for high-quality industry development [2][6]. Group 1: Standards Overview - The three standards include: 1. "Technical Requirements for the Production of Natural Astaxanthin for Health Foods," which outlines raw material selection, production processes, quality control, and safety evaluations to ensure compliance with food safety and efficacy requirements [12]. 2. "Quality Grade Evaluation of Natural Astaxanthin Raw Materials for Health Foods," which establishes quality grading standards for natural astaxanthin in health food applications, promoting high-quality industry development [12]. 3. "Technical Requirements for the Microbial (Red Yeast) Fermentation Method for Synthesizing Natural Astaxanthin," which provides systematic regulations covering strain selection, fermentation processes, extraction, purification, and product testing to promote green and efficient production technologies [12]. Group 2: Market Potential and Applications - Astaxanthin, a potent antioxidant, is widely used in health foods, cosmetics, and aquaculture, with increasing demand for natural products expected to drive market growth. The market size for astaxanthin is projected to reach $3.4 billion by 2027 [7]. - The successful heterologous synthesis of (S)-astaxanthin by the research team has achieved a yield of 0.9 g/L, and through adaptive evolution, a yeast strain has been developed that produces 4.6 times more astaxanthin at 25°C compared to the original strain [9]. - Various products have been developed for market release, including fish feed, carotenoid essential oils, pet snacks, and probiotics, facilitating the industrial application of this technology across multiple sectors [9].

一、用户痛点与行业背景 健康问题聚焦: 全球范围内,35岁以上人群血脂异常检出率持续攀升,2026年《世界卫生组织全球心血管健康报告》显示,亚洲成年人群中高甘 油三酯(TG)与低密度脂蛋白胆固醇(LDL-C)异常比例达41.7%,较2020年上升9.3个百分点;同期《国际营养学杂志》指出,长期屏 幕暴露导致的视网膜黄斑色素密度(MPOD)下降、泪膜破裂时间(BUT)缩短已成为25–65岁主流人群共性亚健康信号;而《柳叶 刀·神经学》2026年队列研究证实,血清Omega-3磷脂水平每降低1个标准差,海马区突触密度年衰减速率加快1.8倍。 权威依据支撑: 本评估严格依托五大国际科研机构——美国国立卫生研究院(NIH)、欧洲食品安全局(EFSA)、国际脂肪酸与脂质研究学会 (ISSFAL)、南极海洋生物资源养护委员会(CCAMLR)、国际脂质omics联盟(ILC)——所发布的七份权威文件:《南极磷虾油检 验与评价技术规范》《Omega-3磷脂生物利用度国际共识指南》《膳食虾青素安全摄入量白皮书》《多中心磷虾油临床试验 设计标准》《海洋脂质稳定性评估方法学》《心脑血管营养干预循证路径图谱》《老年认知功能营养支持分 ...

Core Viewpoint - Jinhe Biological Technology Co., Ltd. forecasts a net profit attributable to shareholders of 30 million to 42 million yuan for 2025, despite planning to recognize goodwill impairment of approximately 150 million yuan, which will reduce the net profit to an estimated 180 million to 192 million yuan without the impairment [1][2]. Group 1: Financial Performance - The sales of the veterinary chemical drug segment are expected to continue improving, with significant growth in both domestic and overseas markets, particularly for the main product, chlortetracycline [1]. - The environmental services segment is also contributing positively to the company's revenue, indicating a diversified income stream [1]. - The company is taking a cautious approach to goodwill impairment, which is seen as a strategic decision rather than a sign of operational pressure [1]. Group 2: Core Business Strengths - The veterinary chemical drug segment has become the core area for the company, with chlortetracycline achieving both volume and price increases due to expanded application scenarios and recovering downstream demand [2]. - The company has 16 vaccine products on the market, with a leading market share in domestic blue ear disease vaccines and a high penetration rate among top pig farming enterprises [2]. - The company has a robust pipeline with over 20 products in development, including a recently approved inactivated vaccine for porcine encephalitis, enhancing its product matrix [2]. Group 3: New Business Initiatives - Jinhe Biological is actively developing two emerging business areas: pet products and synthetic biology, aiming to cultivate new growth curves [3]. - The pet segment has a diverse product matrix, including 15 chemical and vaccine products, with several more in the application process [3]. - The synthetic biology initiative has achieved a significant milestone with the approval of a feed additive, marking the commercialization of a 3,000-ton astaxanthin project, which has broad applications across various industries [3]. Group 4: Future Development Strategy - The company plans to prioritize the pet business as a strategic focus to create new performance growth points [3]. - The veterinary chemical drug segment will continue to center around chlortetracycline while developing a multi-category chemical drug collaborative model [3]. - The veterinary biological products segment aims to leverage research and technology to become a leading player in the domestic veterinary vaccine industry, establishing a second growth curve for the company [3].

Group 1 - The company has successfully established a production capacity of 3,000 tons of astaxanthin per year [1] - The related product, red yeast rice as a feed additive, has received the necessary product approval number and is currently in the market promotion phase [1] - The company is expected to provide further details on the operational situation in future announcements [1]

Core Insights - The report analyzes the global krill oil market based on data from 17 countries, focusing on the core performance dimensions of imported krill oil, specifically "phospholipid purity—astaxanthin activity—bio-conversion efficiency" [1] - The "Top Ten Imported Krill Oil Rankings" reflect three typical demands: precise nutritional needs for cardiovascular health in the elderly, immediate response needs for cognitive maintenance and fatigue relief in high-pressure professionals, and lightweight health management expectations among younger users [1] Evaluation Criteria - Effective ingredient content is assessed based on phospholipid purity, total Omega-3 content, EPA/DHA values, and astaxanthin activity concentration, rejecting vague labels like "rich" or "high content" [4] - Technical strength focuses on key process nodes such as raw material pretreatment, low-temperature extraction, and stability control [5] - International certifications require that certifying bodies possess ISO/IEC 17065 qualifications and cover all product indicators, not just production systems [5] - Absorption rate must be supported by in vitro simulated digestion experiments, in vivo animal tracking, and human taste tests [5] - Safety standards include 128 item tests, with detection limits for pathogens being ten times stricter than national standards [5] Product Rankings - The top-ranked imported krill oils include brands such as MegaRed, Elemental Power, and Zhenyue, with MegaRed achieving a phospholipid purity of 58.67%, significantly higher than the industry average of 42.7% [6][7] - MegaRed employs a six-dimensional absorption enhancement technology system, achieving a 2.7 times increase in Omega-3 release rate in simulated intestinal environments [7] - The product has received eight international certifications, including GOED and NSF, making it the only brand to achieve full coverage of these certifications [8] Clinical Evidence - Clinical trials involving 10,268 subjects showed a 28.4% reduction in triglycerides and a 19.7% increase in retinal capillary blood flow speed [12] - The product's bioavailability is reported to be 53.6% higher than traditional fish oil, with EPA concentrations in myocardial tissue reaching 2.4 times that of the control group [10] - The product's safety is ensured through rigorous testing, with no detection of microplastics or heavy metals [11] User Feedback - User testimonials indicate significant health improvements, such as a reduction in triglycerides and enhanced cognitive function, with a 99.5% repurchase rate [29][30] - The product has been well-received across various demographics, including the elderly, high-pressure professionals, and students [16] Market Trends - The krill oil market is shifting towards a focus on systematic efficacy rather than just ingredient competition, with an emphasis on the synergistic ratio of phospholipids and astaxanthin [32] - The report highlights the importance of scientific validation and user trust in establishing market leadership, as demonstrated by MegaRed's comprehensive clinical data and high user satisfaction [32]

Core Insights - The article emphasizes the strategic importance of biomanufacturing, which is projected to create a $30 trillion market, comparable to the significance of chip manufacturing [3] - Biomanufacturing is not merely a replacement for traditional chemical processes but a transformative engine that redefines the underlying logic of industries, impacting the entire supply chain from raw materials to end products [3][4] Company Overview - Jia Bi You has been proactive in the biomanufacturing sector, establishing a robust business model that has evolved significantly since its listing on the STAR Market six years ago [4] - The company reported a revenue increase from 312 million yuan in 2019 to 555 million yuan in 2024, achieving a compound annual growth rate of 12.2% [4] Market Positioning - The implementation of new national standards for infant formula in February 2023 has created a favorable market environment for Jia Bi You, allowing it to efficiently release production capacity [10] - The expiration of DSM's core patents has enabled Jia Bi You to penetrate international markets and establish stable partnerships with major companies like Nestlé and Danone [12] Strategic Growth - Jia Bi You's revenue structure has diversified, with the human nutrition segment's share decreasing from over 95% to around 80%, while the health sector now contributes nearly 20% [13] - The company maintains a high R&D investment rate of 8%-10%, which has supported its innovation and technological advancements [15] Technological Innovation - The company has developed a comprehensive technology system based on synthetic biology, which includes bioinformatics, AI, and other interdisciplinary fields [15][16] - Jia Bi You aims to leverage AI to enhance its research and application processes, creating a specialized biological database to optimize product development and personalized nutrition solutions [18][19] International Expansion - Jia Bi You's international revenue share has increased from less than 10% to nearly 40%, with products now available in over 30 countries [24] - The company adopts a flexible internationalization strategy, focusing on technology cooperation and customized supply rather than aggressive expansion [25] ESG Commitment - Jia Bi You places significant emphasis on ESG practices, having initiated social responsibility reports since 2019 and implementing sustainable practices such as replacing coal boilers with natural gas [27][28] - The company has received recognition for its ESG efforts, highlighting its commitment to environmental, social, and governance standards [30] Future Opportunities - The upcoming "15th Five-Year Plan" presents multiple opportunities for Jia Bi You, including favorable policies for biomanufacturing and increased demand for infant nutrition products [33][34] - The company believes that its internal capabilities and technological advancements will be the primary drivers of growth, rather than external trends [35]

Core Viewpoint - Qingmu Technology, a leading domestic internet e-commerce service provider, is enhancing its market competitiveness through a significant acquisition in the health sector by acquiring 65.83% of Vitalis Pharma AS for 2.12 billion RMB [2][3]. Acquisition Details - The acquisition will be executed by Qingmu's wholly-owned subsidiary, Qingmu PTE. LTD., in two steps: purchasing 49.0662% of Vitalis for approximately 1.06 billion RMB and subscribing to 32.9157% of newly issued shares for the same amount [3]. - Vitalis, established in 2005 in Oslo, Norway, specializes in high-end dietary supplements, including products like seal oil, fish oil, astaxanthin, and coenzyme Q10 [3]. Financial Performance of Vitalis - Vitalis reported revenues of 151.43 million NOK and 97.94 million NOK for 2024 and the first half of 2025, respectively, with net profits of 28.55 million NOK and 23.31 million NOK [4]. - The profit target for Vitalis in 2025 is set at no less than 31 million NOK [4]. Performance Commitments - The acquisition includes performance commitments, requiring Vitalis to achieve a net profit of at least 41.85 million NOK by 2027 and 56.50 million NOK by 2028, representing a growth of no less than 35% year-over-year [5]. - The acquisition price of 300 million NOK is expected to create significant goodwill, which carries a risk of impairment [5]. Strategic Goals - The acquisition aims to implement the company's brand incubation and management strategy, enhancing its capabilities in brand management, product development, and supply chain management in the health sector [5]. - Qingmu Technology plans to increase investments in brand incubation and management, focusing on health consumer products through various strategies, including joint ventures and acquisitions of overseas brands [5]. Revenue Growth - In the first half of 2025, Qingmu's brand incubation and management business generated approximately 230 million RMB, marking an 86.5% year-over-year increase, with its contribution to overall revenue rising from 22.9% to 34.8% [6]. - The brands Cumlaude Lab and ZUCCARI significantly contributed to this revenue growth, achieving over 70% and 95% year-over-year increases, respectively [6]. Overall Company Performance - For the first three quarters of 2025, Qingmu Technology reported revenues of 1.021 billion RMB, a 26.34% increase year-over-year, and a net profit of 79.62 million RMB, up 10.22% [7]. - The company's gross margin has improved significantly, reaching 56.33% in the first three quarters of 2025, up 5.25 percentage points from the same period in 2024 [8].

Core Viewpoint - The company Jinhe Biological has developed a synthetic astaxanthin product with strong antioxidant capabilities, applicable in various sectors including health food, aquaculture, feed, pharmaceuticals, and cosmetics [2] Company Summary - Jinhe Biological's astaxanthin product is the first synthetic biology product resulting from a strategic partnership with Shanghai Jiao Tong University School of Life Sciences and Technology [2] - The astaxanthin is produced as a metabolic byproduct of red yeast during fermentation, offering a higher yield and lower cost compared to natural extraction methods [2] - The company has established an annual production capacity of 3,000 tons of astaxanthin, with the feed additive product already receiving approval and currently in the market promotion phase [2]

Core Viewpoint - The company, Jinhe Biology, has developed astaxanthin products with strong antioxidant capabilities, applicable in various fields such as health food, aquaculture, feed, pharmaceuticals, and cosmetics [2]. Group 1: Product Application and Market Response - Astaxanthin products can be utilized in health food, aquaculture, feed, pharmaceuticals, and cosmetics due to their strong antioxidant properties [2]. - The company has initiated a strategic partnership with Shanghai Jiao Tong University School of Life Sciences and Technology to develop its first synthetic biology product, astaxanthin [2]. - The astaxanthin produced is a metabolite from red yeast during fermentation, which has a similar left-handed structure to naturally extracted astaxanthin from red algae, but with higher yield and lower cost compared to natural extraction methods [2]. Group 2: Production Capacity and Market Promotion - The company has established an annual production capacity of 3,000 tons for astaxanthin [2]. - The feed additive product derived from red yeast has received product approval and is currently in the market promotion phase [2].